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Available online xxxxBackground: In previous guidelines, acute coronary syndromes (ACS) with new or presumably new left bundle
branch block (LBBB) were an indication for reperfusion treatment, preferably with primary angioplasty. Recent
guidelines also included the presence of right bundle branch block (RBBB) in this recommendation. It was our
objective to evaluate in a population of patients with ACS the differential impact of RBBB and LBBB in prognosis.
Methods: Consecutive patients included prospectively in a single-centre registry of ACS were included in the
study. Patients were analyzed according to baseline ECG characteristics (normal QRS, LBBB or RBBB). Primary
outcome was all-cause mortality at one-year follow-up. We used Cox-proportional hazards models to assess
the predictive value for the primary outcome.
Results:A total of 3990 patients were included in, with amean age of 64 (13) years, 72%males, 3.4%with LBBB and
4.3% with RBBB. Patients with BBB were older, with more previous history of myocardial infarction and coronary
revascularization and higher prevalence of cardiovascular risk factors (except smoking). Medical treatment was
similar but they were less often submitted to angioplasty. In univariate analysis, BBB patients had worst outcome
(Log-rank, p b 0.001), but similar in LBBB and RBBB (Log-rank, p = 0.597). In multivariate analysis, only RBBB
(HR 1.66, 95%CI 1.14–2.40, p= 0.007) is an independent predictor of all-cause mortality.
Conclusions: Patientswith BBBhaveworst outcome after anACS, particularlywith RBBB. For that reason,we should
pay special attention and treat these patients as aggressively as patients with normal QRS duration or LBBB.





Cardiovascular diseases, particularly acute coronary syndromes
(ACS), are an important cause of death in Europe [1]. Althoughmortality
rates of ACS decreased in the last decades, due to major improvements
in treatment, it stabilized in 3–5% [2]. Some special subsets of patients
are at particularly risk and treatment must be optimized in those sub-
groups.
In previous guidelines, treatment of patients with new or presumably
new left bundle branch block (LBBB) should follow recommendations for
ST-segment elevation acutemyocardial infarction (STEMI), with immedi-
ate reperfusion therapy, preferably primary angioplasty [3]. In recent
guidelines, this recommendation has been enlarged for right bundle
branchblock (RBBB) patients [4,5]. However, for RBBB, evidence is less ro-
bust, with fewer available clinical studies and a lower level of evidence.l SantaMarta, Centro Hospitalar
isboa, Portugal.
o).
bility and freedom from bias of
. This is an open access article underThe prevalence of RBBB in the context of ACS is 6–10% [6–12]. In ﬁbrino-
lysis era, bothBBB types hadhigh in-hospitalmortality, of around15–20%,
muchhigherwhen compared to STEMI patients or other ACSwith normal
QRS duration [6–8]. Inmore contemporaneous studies, hospital mortality
is still highest in patients with BBB, particularly new-onset RBBB [9–12].
However, those studies have several limitations. Some are derived from
small samples, others were performed in non-contemporaneous popula-
tions or in randomized (not real-life) populations, some aremeta-analysis
and, in some cases, there are important ethnical differences.
For that reason, it was our objective to assess, in a contemporaneous
real-life population of patients admitted with ACS, the differential im-
pact of LBBB and RBBB in outcome.
1.1. Population and methods
In the present study, we included consecutive adult patients admit-
ted at the Intensive Care Unit of our Cardiology Department with an
ACS, between January 2005 and November 2016. Inclusion criteria
were a history of chest pain at rest or other symptoms suggestive of
an ACS 48 h before admission, with or without new or presumed new












Age (years) 64 (13) 72 (10) 70 (11) 63 (13) b0.001
Male gender (%) 72.0 61.9 74.4 72.3 0.025
Risk factors (%)
Hypertension 64.5 81.5 70.3 63.6 b0.001
Hyperlipidemia 51.3 60.7 54.7 50.8 0.052
Diabetes 25.8 43.0 34.3 24.8 b0.001
Smoking 38.4 15.6 26.2 39.8 b0.001
Previous history (%)
Myocardial infarction 14.5 31.1 19.2 13.7 b0.001
PCI 10.7 17.8 13.4 10.3 0.012
CABG 3.7 14.8 5.8 3.2 b0.001
Stroke/TIA 5.7 9.6 6.4 5.5 0.113
PAD 3.5 3.7 4.1 3.4 0.890
COPD 2.1 4.4 1.7 2.0 0.143
STEMI (%) 65.1 – 51.7 67.0 b0.001
Heart rate (bpm) 78 (20) 89 (21) 82 (22) 78 (20) b0.001
SBP (mmHg) 137 (29) 144 (33) 135 (32) 137 (29) b0.019
Killip class ≥2 (%) 14.8 40.0 23.3 13.4 b0.001
Qualitative LVEF (%) b0.001
N50% 56.2 28.1 54.7 66.6
35–50% 31.0 37.8 35.5 26.6
b35% 8.9 34.1 9.9 6.8
LBBB – left bundle branch block; RBBB – right bundle branch block; PCI – percutaneous
coronary intervention; CABG – coronary artery bypass grafting; TIA – transient ischemic
attack; PAD – peripheral artery disease; COPD – chronic obstructive pulmonary disease;
STEMI – ST-elevationmyocardial infarction; SBP – systolic blood pressure; LVEF – left ven-
tricular ejection fraction.
Table 2











DAPT 91.2 88.9 90.7 91.3 0.621
ACEI/ARB 87.4 88.1 84.9 87.5 0.588
Beta-blockers 83.7 79.3 84.3 83.8 0.358
Statins 91.7 88.9 90.1 91.9 0.336




6.4 6.7 9.9 6.2 0.162
Cardiac arrest 7.4 8.1 13.3 7.0 0.016
Complete AV block 2.6 3.0 1.2 2.6 0.474
Major bleeding 0.4 0 1.2 0.4 0.447
Stroke/TIA 1.0 2.2 1.2 1.0 0.338
Outcome (%)
In-hospital mortality 5.3 8.1 10.5 5.0 0.002
30-day mortality 5.7 8.1 13.4 5.7 b0.001
One-year mortality 9.3 17.0 19.2 8.6 b0.001
DAPT – double antiplatelet treatment; ACEI – angiotensin converting enzyme inhibitor;
ARB – angiotensin receptor blocker; PCI – percutaneous coronary intervention; TIA tran-
sient ischemic attack.
32 A.T. Timóteo et al. / IJC Heart & Vasculature 22 (2019) 31–34biomarkers of myocardial necrosis (with a rise and/or fall of levels).
Acutemyocardial infarctionwas deﬁned according to type 1myocardial
infarction universal deﬁnition [13]. STEMI was deﬁned by the presence
of persistent (N30min) ST-segment elevation. All other cases were con-
sidered non-ST-segment elevation ACS (NSTACS).
Patients were included prospectively in the centre's ACS registry.
Datawas collected in a dedicated computer database. It included demo-
graphic data, clinical and patient management information, as well as
in-hospital outcome. Hypertension, diabetes and hyperlipidemia were
deﬁned as previously known or on speciﬁc therapy. If the patients had
smoked during the previous sixmonths, theywere classiﬁed as smokers
and were self-reported. All decisions on patient management strategy
(including referral for an invasive strategy and type of revasculariza-
tion) were left to the attending physician.
Follow-up was obtained by a dedicated nursing team in every pa-
tient that survived to discharge and was obtained by telephone inter-
view with the patient or with a close family member and/or by review
of the medical record. Follow-up was completed in 99.7% of patients.
Our primary endpoint was all-cause mortality during one-year follow-
up, counted from admission. Mortality was also analyzed during hospi-
tal stay and at 30-day follow-up. Mean hospital stay was 8 days, with a
median stay of 6 days and interquartil range of 5–9 days.
The authors assert that all procedures contributing to thiswork com-
ply with the ethical standards of Helsinki Declaration of 1975 and that
this research does not involve human and/or animal experimentation.
1.2. Statistical analysis
Patients were divided in three groups according to the presence of
LBBB, RBBB or normal QRS duration in the admission ECG. Normality
of continuous variables was tested with the Kolmogorov-Smirnov's
test and homogeneity of variance was tested with Leven's test. All con-
tinuous variables showed normal distribution. Continuous variables are
reported asmean and standard deviation (SD) andwere comparedwith
ANOVA-test. Categorical variables are reported as percentages and dif-
ferences between-groups were tested with the chi-square test or
Fischer's exact test, as appropriate.
Survival analysiswas testedwithKaplan-Meier curves andwith Log-
rank test. We used Cox-proportional-hazards regression models to
identify potential predictors of the primary outcome. We set a p level
for inclusion in the multivariate model at 0.05. The estimates of the as-
sociation between predictors and outcome are presented as hazard ra-
tios (HR) and 95% conﬁdence intervals (CI).
For all statistical analysis, we used the IBM SPSS statistical software
package (version 19.0.0.2). All tests were two-sided with a critical
value of 0.05 for statistical signiﬁcance.
2. Results
We included in the present study 3990 patients. QRS duration was
normal in the majority of patients. LBBB was present in 3.4% and RBBB
in 4.3% of patients. Mean age was 64 (13) years, with a predominance
of male gender (72%). Patients with BBB were older and had more car-
diovascular risk factors, particularly LBBB patients, with the exception
of smoking that was less prevalent in both BBB groups, mainly in LBBB
patients (Table 1). RBBB group hadmoremale patients, followed by nor-
mal QRS group. Regarding previous medical history, baseline character-
istics were also signiﬁcantly worse in both groups of BBB, particularly
in LBBB group, with more frequent history of myocardial infarction and
myocardial revascularization. Killip class on admission was also worse
in BBB groups. Heart rate and SBP was higher in LBBB.
Pharmacological treatmentwas similar in all groups; however, coro-
nary angioplasty was less performed in patients with BBB, particularly
LBBB (Table 2). Thrombolysis was used in 5.3% of all patients (8.1% of
STEMI cases), 3% in RBBB group, 3% in LBBB group and 5% in the group
with normal QRS, with most cases being referred to our departmentfor rescue PCI. Complications occurred at a similar rate across all groups,
with the exception of cardiac arrest, more frequent in RBBB group. All
mortality endpoints were more frequent in BBB, but slightly higher in
the RBBB group. In univariate survival analysis, BBB patients had
worse outcome (Log-rank, p b 0.001), but similar in LBBB and RBBB
(Log-rank, p= 0.597).
Patients with RBBB and NSTACS, compared to patients with STEMI,
have more frequently hypertension, previous revascularization, higher
systolic blood pressure on admission and better Killip class (Supple-
mental Table). They receivedmore often statins butwere less often sub-
mitted to coronary angioplasty. Mortality was higher than usual in both
groups (STEMI and NSTACS), particularly in the STEMI group.
In Cox-proportional hazards univariate analysis, both LBBB and
RBBB were predictors of all-cause mortality at one-year follow-up
(Table 3). The other potential predictors of outcomewere age, diabetes,
Table 3
Cox proportional hazard regression analysis (unadjusted and adjusted).
Univariate p-value Multivariate p-value
Normal QRS Ref. – Ref. –
LBBB 2.06 (1.35–3.15) 0.001 1.13 (0.72–1.79) 0.584
RBBB 2.37 (1.66–3.4) b0.001 1.66 (1.14–2.40) 0.007
Results are presented as Hazard ratios and 95% conﬁdence intervals.
Adjusted for: age, heart rate, systolic blood pressure, previous revascularization, diabetes,
Killip class ≥2, doubles antiplatelet treatment, renin-angiotensin-aldosterone system
blocker, beta-blockers, statins, and percutaneous coronary intervention.
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sure, Killip class and the use of double antiplatelet treatment, renin-
angiotensin-aldosterone system antagonists, beta-blockers and statins
and percutaneous coronary interventions. After adjustment, LBBB is no
longer an independent predictor of all-cause mortality but RBBB re-
mains an important predictor (HR 1.66, p= 0.007) (Fig. 1).
3. Discussion
In our sample of patients with ACS, 7.7% of the patients had any form
of BBB, particularly RBBB in 4.3%. In general, patientswith BBB hadworse
baseline characteristics, particularly regarding demographic variables,
cardiovascular risk factors, previous cardiac history and presentation,
with worst data in LBBB patients. Treatment was, however, similar in
all groups with the exception of coronary angioplasty, less frequently
performed in LBBB, followed by RBBB. The outcome was signiﬁcantly
worse in all form of BBB, but patients with RBBB had higher mortality.
Inmultivariate analysis, and after adjustment, RBBB remains an indepen-
dent predictor of one-year all-cause mortality.
Our prevalence of RBBB and LBBB is slightly lower than previously
reported, particularly when compared with older studies (N10 years)
[6,7]. In recent years, however, lower rates have been described, around
4–7% for LBBB and 4–10% for RBBBwith our results close to these lower
limits [8–10]. Our study only included patients admitted in the Cardiol-
ogy department, which is a tertiary center, withmost patients being re-
ferred for invasive treatment strategy. This has important implications
in our population, with N50% of patients being STEMI and possibly in-
ducing some referral bias for BBB patients that might explain this dis-
crepancy. In a head-to-head comparison, in non-contemporaneous
studies, BBB patients were older, with more comorbidities and heart
failure, similar tomore recent studies and also to our own results [6–12].
Older studies reported worse outcome in patients with BBB. In-
hospital mortality was reported of around 20% and similar in both
types of BBB, which was higher when compared to STEMI patientsFig. 1.Multivariate Cox-proportional hazards survival curve.[6,8,11]. In studies with a very long-term follow-up, mortality rates in
patients with BBB were 90–94%, much higher when compared to pa-
tients with ACS and normal QRS (77%) [9]. A large meta-analysis con-
ﬁrmed that RBBB patients had the highest mortality (in-hospital and
long-term), but in this analysis there was considerable heterogeneity
across included studies [11]. In more recent studies, mortality rates in
this subgroup did not improvemuch, despite substantial improvements
in treatment [10–12]. Studies that compared new/old or persistent/
transient BBB, consistently showed that new and permanent BBB
(particularly RBBB), was associated with the worst outcome [6,7,12].
Thus, patients with new and permanent BBB are a subset of patients
at particularly higher risk and they represent a substantial proportion
of patients. In a cohort of patients from 1998 to 2008, new BBB repre-
sented 32.5% of all BBB (36% for RBBB and 27% for LBBB) [6]. A more re-
cent cohort (2006–2008) showed lower incidence, with 16% of all RBBB
and 13% of all RBBB being new [8]. Permanent BBB is believed to repre-
sent 35% of all new RBBB and 40% of all new LBBB [6].
However, those studies have several limitations as already pointed
out and a contemporaneous study, with a large real-life population
and with head-to-head comparison was necessary to conﬁrm previous
information and to validate recent guidelines. Our analysis, in a large co-
hort of patients, demonstrated that both types of BBB had worse out-
come in medium-term follow-up, with in-hospital mortality of 8–10%
and one-year all-cause mortality of 17–20%. These results seem to be
better that previously reported, probably reﬂecting the optimized phar-
macological treatment with higher use of drugs with important impact
in prognosis. However, coronary angioplasty was signiﬁcantly less per-
formed in BBB patients when compared to normal QRS patients and this
is an important cause for the worse results obtained in these groups,
particularly in patients with LBBB. In RBBB patients, the outcome was
persistently worst, even after adjustment for other independent predic-
tors of mortality. One possible explanation is that these patients had
more often cardiac arrest in the index hospitalization. Coronary anat-
omy might also be an important explanation for the results obtained;
in previous studies, angiographic predictors of RBBB were proximal oc-
clusion and TIMI ﬂow 0/1 of the infarct related artery, all known predic-
tors of unfavorable outcome [10]. However, in our study, not all patients
were submitted to coronary angiography, particularly in BBB groups,
and this information is not available in our data registry. For that reason,
it was not possible to assess the impact of coronary anatomy in RBBB in-
cidence and outcome. We believe that there might be some differences
in culprit coronary artery or coronary anatomy related to BBB thatmight
have implications in terms of outcome.
3.1. Limitations
This is a retrospective study, with all the limitations previously de-
scribe for this type of study. Some information was not possible to col-
lect retrospectively. For instance, it was not possible to assess if BBB
was new or old or if it was transient or permanent. We also do not
have information about concomitant presence of anterior or posterior
left hemiblock with RBBB. Another limitation is the lack of detailed in-
formation about quantitative left ventricular ejection fraction, tropo-
nins, completeness of revascularization, PCI delays, and concomitant
causes of RBBB (such as pulmonary hypertension, pulmonary embolism
or right ventricle myocardial infarction). Our sample of patients with
BBB is relatively small. The type of follow-up used in the present study
did not allowed an analysis of other endpoints, such as myocardial in-
farction or other cardiovascular events. We only have data for one-
year follow-up. A longer follow-up might have provided additional im-
portant information.
4. Conclusions
Patients with bundle branch block had worse baseline characteris-
tics, especially patients with left bundle branch block. In long-term
34 A.T. Timóteo et al. / IJC Heart & Vasculature 22 (2019) 31–34follow-up, they also had worse outcome, with higher all-cause mortal-
ity, particularly in the presence of right bundle branch block. Our results
support international recommendations. We should be aware and pay
special attention to these patients (particularly with right bundle
branch block), and treat them at least as aggressively as patients with
normal QRS duration, not only concerning pharmacological treatment
but also in terms of invasive strategy.
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